Table 4.
Selected trials of radiation therapy for treatment of T4 laryngeal cancer
| First Author |
Year | T4 pts |
N+ (%) |
% TL- PORT |
% RT alone |
% chemo | Chemo used | OS % (yrs) |
CSS % (yrs) |
DFS % (yrs) |
DMFS % (yrs) |
LC % (yrs) | LRC % (yrs) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nishimura | 2007 | 8 | 100 | 100 | CDDP/5FU | 71 (5) | |||||||
| Hinerman | 2007 | 22 | 22 | 100 | 67 (5) | 87 (5) | 100 (5) | 82 (5) | 78 (5) | ||||
| Ampil | 2004 | 28 | 32 | 100 | 43 (7) | 30 (7) | |||||||
| Harwood | 1981 | 56 | 0 | 100 | 56 (5) | ||||||||
| Jesse | 1975 | 48 | 37 | 33 | 54 (4) | ||||||||
| Fagan | 1998 | 37 | 19 | 30 | 86 | ||||||||
| Yuen | 1984 | 57 | 16 | 35 | 63 (5) sx alone/94 (5) CMT | 68 sx alone/95 CMT/77 overall | |||||||
| Parsons | 1998 | 43 | 53 | 100 | 4 | CDDP/5FU | 37 (5) | 47 (5) | 52 (5); | ||||
| Mendenhall | 1998 | 30 | 100 | 89 (5) glottis/ 56 (5) supraglottis | |||||||||
| Paisley | 2002 | 12 | 0 | 100 | 39 (5) | 42 (58 after salvage sx) | |||||||
| Sykes | 2000 | 41 | 0 | 100 | 61 (5) | 73 (5) | 72 (5) | ||||||
| Karim | 1987 | 117 | 33 | 100 | 63 glottic xrt alone/70 supraglottic xrt alone 85 glottic xrt+salvage sx/ 84 supraglottic xrt+salvage sx | ||||||||
| Croll | 1989 | 28 | 100 | 75 (5) | |||||||||
| Adelstein | 1998 | 16 | 100 | 100 | 63 (2 - median) | ||||||||
| Guadagnolo | 2005 | 13 | 54 | 100 | 100 | induction - PF, TPF, TPFL, con - cis, doxetaxel | |||||||
| Nguyen-Tan | 2001 | 90 | majority | 17 | CDDP/5FU | 62 (5) overall/70 (5) sx+/− xrt/ 19 (5) xrt alone +/− salvage sx/ 36 (5) xrt+chemo | |||||||
| Knab | 2008 | 32 | 56 | 100 | 59 ind/100 concurrent | Paclitaxel/5FU/hydroxurea, carboplatin | 53 (4) | 67 (4) | 71 (4) | 83 (4) | 71 (4) | ||
| Henry | 1975 | 86 | 37 | 100 | 48 (3); 25(5) | ||||||||
| Kligerman | 1995 | 20 | 35 | 76 | 48 | ||||||||
| Worden | 2009 | 27 | 53 | 100 | 100 ind/75 concurrent | cis/carbo,5FU (induction), cis (concurrent) | 78 (3) | 80 (6) |
Abbreviations: TL-PORT, Post-Laryngectomy Radiation Therapy; RT or xrt, Radiation Therapy; OS, Overall Survival; CSS, Cause Specific Survival; DFS, Disease Free Survival; DMFS, Distant Metastases Free Survival; LC, Local Control; LRC, Loco-regional Control; CDDP, Cisplatin; 5FU, 5-Fluorouracil; sx, Surgery; PF, cisplatin 5FU; TPF, Docetaxel cisplatin 5-fluorouracil; ind, induction.